The management of a pregnant patient in radiation oncology is an infrequent event requiring careful consideration by both the physician and physicist. The aim of this manuscript was to highlight treatment planning techniques and detail measurements of fetal dose for a pregnant patient recently requiring treatment for a brain cancer. A 27-year-old woman was treated during gestational weeks 19-25 for a resected grade 3 astrocytoma to 50.4 Gy in 28 fractions, followed by an additional 9 Gy boost in five fractions. Four potential plans were developed for the patient: a 6 MV 3D-conformal treatment plan with enhanced dynamic wedges, a 6 MV step-and-shoot (SnS) intensity-modulated radiation therapy (IMRT) plan, an unflattened 6 MV SnS IMRT plan, and an Accuray TomoTherapy HDA helical IMRT treatment plan. All treatment plans used strategies to reduce peripheral dose. Fetal dose was estimated for each treatment plan using available literature references, and measurements were made using thermoluminescent dosimeters (TLDs) and an ionization chamber with an anthropomorphic phantom. TLD measurements from a full-course radiation delivery ranged from 1.0 to 1.6 cGy for the 3D-conformal treatment plan, from 1.0 to 1.5 cGy for the 6 MV SnS IMRT plan, from 0.6 to 1.0 cGy for the unflattened 6 MV SnS IMRT plan, and from 1.9 to 2.6 cGy for the TomoTherapy treatment plan. The unflattened 6 MV SnS IMRT treatment plan was selected for treatment for this particular patient, though the fetal doses from all treatment plans were deemed acceptable. The cumulative dose to the patient's unshielded fetus is estimated to be 1.0 cGy at most. The planning technique and distance between the treatment target and fetus both contributed to this relatively low fetal dose. Relevant treatment planning strategies and treatment delivery considerations are discussed to aid radiation oncologists and medical physicists in the management of pregnant patients.
| INTRODUCTION
Patients requiring radiation therapy are seldom simultaneously pregnant. However, when both conditions apply, unique considerations are required from the radiation oncologist and the medical physicist.
Especially at doses exceeding 10 cGy, the deterministic effects of ionizing radiation on the developing fetus are moderately understood, and linear extrapolations of stochastic risk estimates are commonplace. 1, 2 Radiation therapy can play a net-beneficial role in the management of a pregnant patient, but depending on the treatment site, special treatment planning techniques to reduce peripheral dose and/or fetal radiation shields may be necessary.
While breast cancer and hematologic malignancies make up the preponderance of cancers seen in a pregnant population, other tumor types are found with some frequency, including brain tumors. 3 Common brain malignancies (e.g., gliomas) found in a patient population of child-bearing age are often treated with shaped radiation fields or arcs that enter the patient's head from many angles, including so-called "vertex" beams. It may be possible to achieve a clinically acceptable plan while substantially reducing peripheral dose by modifying these standard treatment planning strategies. Numerous reports have detailed planning strategies to reduce peripheral dose. [4] [5] [6] [7] [8] [9] [10] While IMRT is a common choice for intracranial treatments, IMRT often results in higher peripheral dose than 2D-or 3D-conformal treatment techniques.
5,10
The purpose of this manuscript was to detail the special considerations for a pregnant brain cancer patient recently treated in our clinic, including treatment plan design for both a Varian TrueBeam system and an Accuray TomoTherapy HDA system, peripheral dose estimation and measurement, and other patient management strategies. While prior reports have provided estimates of peripheral dose for various combinations of beam energy and geometry, these reports often apply to a prior generation of treatment delivery system. 1, [4] [5] [6] [10] [11] [12] [13] [14] The present manuscript details fetal dose measurements on current-generation treatment delivery systems and summarizes the anticipated risks to the patient's fetus using published guidance. Finally, we aim to briefly summarize some of the relevant literature on fetal dose in radiation therapy.
| ME TH ODS AND MATERIALS

2.A | Patient details
The patient detailed in this report is a 27-year-old pregnant female.
She was simulated for treatment to her grade 3 astrocytoma resection cavity during gestational week 17. The patient was prescribed 50.4 Gy in 28 fractions to a primary target volume to be followed sequentially by a 9 Gy boost in five fractions to a smaller volume.
Medical images with delineated target volumes are shown in Fig. 1 .
Standard departmental brain planning constraints were ordered for this patient, including D(0.03 mL) < 54 Gy for the brainstem, optic chiasm, and optic nerves; mean dose < 35 Gy and D(0.03 mL) < 40 Gy for the cochleae; D(0.03 mL) < 7 Gy for the lenses of the eyes; and D(0.03 mL) < 45 Gy for the spinal cord. At least 95% of the target volume was covered with 99% of the prescription dose in each treatment plan, and target hotspots were maintained less than 110%. | 369 symphysis were measured from a fixed radio-opaque marker placed on her chin. Palpation of the uterine fundus was not achieved in our department; instead, a brief consultation with diagnostic radiology immediately prior to her CT simulation measured her uterine fundus to be 4 cm inferior to her umbilicus using a portable ultrasound unit.
The total distance from each point of interest to the target volume was later determined by measuring the distance between the radioopaque marker and the segmented target volume in the simulation CT image. Finally, we assumed superior progression of the patient's uterine fundus at a rate of 1 cm/week and that the patient would be treated during gestational weeks 19-25. 1 Table 1 shows the distances from the target volumes to the points of interest.
Our institution's Health Insurance Portability and Accountability Act (HIPAA) Privacy Officer has reviewed this manuscript to ensure compliance with our institution's standards for protected health information. Institutional Review Board review was not required.
2.B | Treatment plans
In an attempt to use available department resources to reduce fetal dose, four potential treatment plans were developed for the patient: 
2.C | Estimates of fetal dose
Fetal dose was estimated using the prescribed doses given previously, the distances from treatment volumes to points of interest ( 
2.D | Measurement of fetal dose
Fetal dose was measured at each of the four points of interest identified in Table 1 Fig. 2 . The measurements from the three TLDs were averaged together for each point of interest for each treatment plan.
While out-of-field dose has minimal dependence on depth, the superficial dose is markedly higher than the rest of the depth-dose curve; the bolus was used to position the TLDs beyond this superficial region. 
2.E | Patient imaging
The patient was imaged for treatment planning using our department's CT simulator. A 0.5 mm lead-equivalent apron was placed around the patient's abdomen and pelvis during her CT scan; this type of apron may reduce the CT dose to the fetus by 90% or more. 16 other references can be used to estimate fetal dose. 17 As is standard at our institution for pregnant patients, iodinated contrast was not used for the patient's simulation CT scan. Iodine-based contrast does present some fetal risks. 18 For image guidance during patient treatment, the intended strategy depends on the treatment. For the TrueBeam plans discussed above, orthogonal planar 2D kV-kV imaging would be entirely sufficient to align the cranium with five of the available six degrees-offreedom. If cone-beam CT (CBCT) were required, it could be performed with minimal fetal dose on a modern TrueBeam system.
Scaling organ doses previously published for a prior generation of Varian CBCT system by the CTDI ratios between the older On-Board Imager (OBI) CBCT system and the TrueBeam CBCT system, one could estimate up to 0.0006 cGy fetal dose per "head" CBCT and up to 0.005 cGy fetal dose per "thorax" CBCT (using kidneys as a conservative surrogate for the fetus). [19] [20] [21] TomoTherapy image guidance would be performed with the "coarse" MVCT protocol with 3 mm slice thickness to minimize the MU required for MVCT imaging.
| RESULTS
The patient started treatment during gestational week 19 and finished treatment during gestational week 25, as anticipated. All four treatment plans easily met the planning goals listed in the Patient Details subsection above and were considered equivalent in terms of plan quality. Estimated fetal dose derived using the techniques described above are shown in Table 2 Inverse-square scaling may be appropriate given that the preponderance of peripheral dose for this study originates as leakage from the treatment head itself. 22 The measured doses for the four plans at the four points of interest are also given in Table 2 . The measured doses are in fairly good agreement with the estimated doses (adjusted for plan modulation and inverse-square law where necessary). The uncertainty in the TLD measurements was estimated to be 5%, given the very low doses used to calibrate the TLD batch. The ion chamber leakage signal was estimated to be approximately 6.5% of the measurement signal; although this leakage was nulled at the electrometer, we estimate the total uncertainty in our ion chamber measurements to be Based on the gestational age of the fetus at the time of irradiation and the low fetal dose levels, minimal effects are expected for the fetus. 1, 2 The dose levels are below threshold doses for malformation (including microcephaly) and drop in intelligence quotient.
Based largely on follow-up observation of the atomic bomb survivor cohort, the absolute risk of inducing a fatal childhood cancer before the age of 19 may be as high as 0.06% per 1 cGy. 2 Table 4 from ICRP Report 84 shows that the risk of a fatal childhood cancer from the 1 cGy fetal dose for treatment plan 3 in this study increases the 0.3% baseline risk to 0.4%. The patient was consented for treatment only after this information was provided to her and her questions were answered satisfactorily by the attending physicist and physician. All four treatment plans investigated herein produced maximum measured fetal doses less than the 5 cGy limit given in Task Group   Report 36 table VI for "little risk of damage" to the fetus, and all four plans were clinically acceptable to the physician. Estimates of fetal dose for each plan were made using published literature, and measurements of fetal dose were made for each plan using a modified anthropomorphic phantom. Measurements and estimates were performed at points of interest that bracketed the potential locations of the fetus during the duration of the patient's treatment. The treatment plan with the lowest measured fetal dose was selected for patient treatment.
The estimated doses to the points of interest were adjusted using the MU-to-cGy ratio for the TrueBeam treatment plans, as well as using the inverse-square law when peripheral dose estimates
were not available at the distances given in Table 1 6 MV-FFF for a 3D brain plan resulted in a 20% reduction in unshielded fetal dose. 5 As a note of caution, using 6 MV-FFF for T A B L E 2 Estimated and measured fetal doses to the points of interest in Table 1 
